itive secretin test and gastrin unresponsiveness to meal stimulation. Angiography and computed tomography (CT) scan were negative and transhepatic venous sampling (THVS) suggested localization of a tumor in the region of the triangle of the head of the pancreas, the wall of the duodenum, and pylorus. At laparotomy, only a peripancreatic lymph node in the region of the head of the pancreas was found that contained gastrinoma cells. After the operation, the patient did not improve substantially, acid secretion remained high, and treatment with SMS has been continued until the present. Histologic confirmation of gastrin producing tumors was obtained in seven of the 10 patients. Three patients did not have laparotomies and were diagnosed on the basis of raised basal and secretin-stimulated gastrin, increased basal acid secretion with a BAO/MAO ratio of greater than 0.6.
RESULTS

Acute Eflects of SMS
Basal and secretin-stimulated gas&in was determined in these eight patients 6 hours after subcutaneous administration of 100 pg SMS. SMS significantly lowered both basal and secretion stimulated gastrin. Of the eight patients, basal serum gastrin became normal in five and in only two did the secretinstimulated values fall below the upper limit of normal of less than 100 pg/mL increment above basal.
Acute effects of SMS on basal and pentagastrin-stimulated (6 to 12 &kg) acid secretion were obtained in eight of 10 patients 1 hour after subcutaneous injection of 100 pg SMS 201-995. Only in patients who had not had gastrectomies were studies of acid secretion performed. Antisecretory agents were discontinued 24 hours before study. Gastric juice, as well as blood samples, was collected during a 4-hour basal period, then at hourly intervals after subcutaneous administration of 50 to 100 pg of SMS administered every 6 hours. Before SMS treatment, mean basal acid output was raised and the response to pentagastrin blunted, resulting in a high BAO/MAO ratio in gastrinoma patients. SMS lowered basal acid secretion from 25 to 2.6 mEq/h, with an insignificant decrease in the pentagastrin-stimulated acid output, thus normalizing the BAO/MAO ratio. In seven of these eight patients, the BAO dropped to less than 5 mEq/h.
Long-Term Eflects of SMS 201-995
The long-term effects were studied in eight patients who were treated with 400 to 500 rg SMS for 2 to 12 months. Biochemical responses were determined in five patients, two who had gastrectomies in whom only gastrin was measured and three who had basal and pentagastrin-stimulated acid studies and secretin tests after more than 5 months of treatment, before and 48 hours after withdrawal of SMS.
Basal gastrin gradually increased and basal acid output remained stable or increased slightly over a 3-year period. Secretin-stimulated gastrin remained abnormal in the three Merebolsm, Vol39, No 9, SuppI (September), 1990: pp 156-162 patients, but was suppressible by SMS both acutely and over a long-term period. Similarly, gastric acid responses to pentagastrin remained abnormd and no tachyphylaxis to SMS developed with time.
Six of the eight had improvement in their primary symp toms and two patients continued to have symptoms of abdominal pain, nausea, vomiting, and weight loss. Two patients who failed to respond had a progressive increase in gastrin concentration over a 7-month period. Despite increasing the dose to 1,000 li&ld, gastrin levels remained elevated.
Three patients demonstrated important nuances not recorded heretofore and their histories and findings will be presented briefly.
CASE REPORTS
Patient 1
R.B. was a 39-year-old man who developed epigastric pain, increased bowel movements, and wei& loss in 1979 and was diagnosed as having Zollinger-Ellison syndrome. Serum gas&in level at that time was between 20,000 and 40,000 pg/mL. Upper endoscopy showed multiple ulcers and investigation showed a large pancreatic mass and multiple liver metastases. He underwent 80% pancreatectomy and lefI hemihepatectomy in March 198 1. Postoperative serum gastrin level dropped to between 3,608 and 7,800 pgjmL. In July 198 1, the patient developed basal acid secretion of 3 I mEq/h while on a high dose of cimetidine and underwent a total gastrectomy. Chemotherapy using 5-5uorouracil and streptozotocin was started in view of multiple liver metastases. This was succes&l in suppressing the gas&in secretion to below 2,ooO pg/mL for 2 years. Subsequently, the serum gastrin level increased again to 16,000 pg/mL and the me&static tumors in the liver enlarged in size gradually despite chemotherapy and SMS treatment. Debulking of the tumor masses in the liver was performed and the patient was restarted on chemotherapy with little response. He subsequently developed overwhelming streptococcal pneumonia and disseminated pulmonary and cardiac aspergillosis and died. In the last 2 months of life, the patient was noticed to have a Cushingoid facies. Plasma cortisol level (75 &dL) and plasma ACTH level (248 pgjmL) were both elevated. The course is illustrated in Fig 1. No further biochemical test was performed as the patient was deemed too ill. Autopsy examination revealed enlargement of both adrenal glands to twice their normal size with microscopic hyperplasia. There was also widespread metastatic disease in the pancreatic bed and liver. The pituitary gland was normal.
Patient 2
D.K. is a 30.yearold yoman who suffemd from recurrent epigastriic pain since 1969 at the age of 14 requiring regular antacid treatment. She developed bleeding duodenal ulcer at the age of 23 and underwent truncal vagotomy and pyloroplasty. Since then she had persistent ulcer pain and was treated with an Hz-receptor antagonist. She had remained in relatively good health until 1 year before admission. She was evaluated for deterioration of ulcer symptoms and was found to have three distal antral ulcers and marked duodenal erosions at gastroduodenoscopy. Serum gastrin level was elevated to 1,700 (normal < 150) pg/mL and serum gash-in level rose to 5,496 pgjmL at 5 minutes after secretin-stimulation. Over the year, she also noticed the development of Cushingoid facies and hirsutism, acanthosis, and plethora with proximal muscle weakness. Urinary free cortisol concentrations were markedly elevated at 962 mg/24 hours (normal c 0.5). Plasma cortisol levels were elevated with a morning level of 40 &dL (normal 10-25) and evening level of 33.4 &dL (normal 3-16). Overnight dexamethasone test failed to suppress the,,moming plasma cortisol. However, the morning plasma ACTH level was normal at 76.6 pg/mL (normal 60-90). Plasma corticotropin-releasing factor (CRF) was 46 pg/mL (normal < 100). Plasma DHEA and testosterone were normal. CT scan of the abdomen showed a mass in the tail of the pancreas, but both adrenal glands were normal. CT scan of the pituitary was normal. Mesenteric angiography demonstrated a mass in the tail of the pancreas without apparent liver me-
tastaSeS.
She underwent laparotomy on September 19, 1985 . A distal pancreatectomy with splenectomy was performed, removing a 5-cm tumor. Both adrenal glands were found to be slightly enlarged. There was no evidence of metastatic tumor in the abdomen. Postoperatively, the basal serum gastrin level returned to normal at 135 pg/mL, but the gastrin response to secretin-stimulation remained abnormal. The Cushingoid facies and the myopathy mgremed within 2 months. The patient had no further evidence of active ulcer disease and cimetidine treatment was stopped. She also noticed regression of angioneurotic edema after the operation.
Histologic examination of the resected specimen confirmed the presence of an islet cell tumor. Immunohistochemical staining was positive for gastrin, ACTH, serotonin, (Y-and &melanocyte-stimulating hormone (MSH), neuron-specific enolase, chromogmnin, somatostatin, and vasoactive intestinal polypeptide. However, staining for corticotropin-releasing factor was, equivocal. Unfortunately, liver metastases were detected on CT scan 6 months abler initial operation and both the basal semm gastrin and the response to secretin was now abnormal. Resection of a liver metastasis was performed out and the basal serum gastrin level returned to normal, but the response to secretin remained abnormal. Immunohistochemical staining of the metastatic tumor was positive for gastrin but negative for ACTH. In July 1988, she received a 2-week course of chemotherapy, including streptozotocin, 5-fluorouracil, and Adriamycin, with little response. In September 1988, the patient received chemoradiation of the hepatic metastases with yttrium 90 beads without arrest of progress of the tumor growth. In September 1988, she again noticed development of Gushing's features with elevation in plasma cortisol, which required medical treatment with amino$lutethimide. Her course is illustrated in Fig 2. 
Patient 3
G.V. is a 19-year-old woman who had recurrent epigastric pain since 1983. In March 1985, she developed upper gastrointestinal bleeding from a duodenal ulcer. Laparotomy revealed a 7 X 8-cm mass at the tail of the pancreas, with large periportal lymph nodes and multiple liver nodules. Liver biopsy confirmed the presence of metastatic islet cell carcinoma. Vagotomy and oversewing of the ulcer was performed. A serum gastrin level was checked after the operation and was mildly elevated at 162 pgjmL, with a peak level of 225 pg/ mL 5 minutes after secretin infusion. Fasting cortisol was 11.7 & dL, and ACTH 60 pg/mL. She was well until February 1986 when she developed frequent bouts of abdominal pain and vomiting. She also noticed the development of increased acne, facial puffiness, and tnmcal obesity. A secretin test showed a basal serum gastrin level of 220 pg/mL, with a peak of 288 pg/mL at 10 minutes. Morning (8 AM) plasma cortisol level was elevated at 32.6 &dL (normal 10-25) and evening (10 PM) plasma cortisol was 18.8 &dL (normal 3-16). Both low-dose and highdose dexamethasone administrations showed suppre&on of plasma cortisol to less than 5 118/dL and plasma ACTH remained normal at 60 pg/mL (normal c 100 pg/mL). CT scan of the abdomen showed numerous hepatic me&stases with multiple masses in almost the entire pancreas. There were also numerous periaortic and pericaval lymph nodes, and both adrenal glands were slightly enlarged. She was diagnosed as having metastatic malignant gastrinoma with Gushing's syndrome. She was placed on treatment streptozotocin. Ultimately, after a period of 3% years, the tumor escaped treatment and daspitefuttherchemotharapauticagentsand debulking of tumor metastases, the course was relentless and SMS appeared to have no effect. Terminally, the tumor appeared to produce ACTH or a corticotragin-releasing factor and cortisol levels increased with the develwmant of Cushing's syndrome. The course in D.K., a patient with a metastatic corticotropin-releasing factor (CRF)-producing tumor, in whom there was an excellent initial rasgonse to resec-~~~~~~~ afa~.~~~~ decreased, as we8 as cortisol, but the gastrfn msponse to secretin remained abnormal indicative of persistence of the tumor. SMS was without effect and chemotherapy with 5-fluomuracil and streptnzoto& was akro ineffective. To control the Gushing's syr&ome. aminoglutathimlde was usad and the tumor was brought under control with yttrium SO parfusion of the Ever metastases.
OCTAEOTIDE AND NEUROENDOCRINE TUMORS
with SMS in May 1986, with escalating doses from 200 &d to 2,000 .&d by April 1989. In March 1987, she had a bone scan because of complaints ofgeneralized body pain and was found to have extensive bone metastases. Between March 1987 and April 1988, the patient received direct hepatic irradiation, but refused intrarterial chemotherapy. In October 1988, she developed right hip pain due to a pathologic fracture for which she received direct radiation. Her ulcer symptoms are controkd on SMS, and CT and angiogram in February 1989 showed a reduction in the liver and pancreatic masses. The course of her serum gastrin and gastric acid secretion are shown in Fig 3 and the reduction in hepatic metastases coincident with the development of bone metastases in Fig 4A-D. 
DISCUSSION
Our 10 patients represent all three of the heterogeneous varieties of gastrinoma syndrome: the benign sporadic, MEN-1, and the metastatic. All the benign tumors were found to be extrapancreatic and in sites similar to those previously reported.'4*" In eight of our patients with gastrinoma in whom we were able to evaluate acid secretion, SMS in doses of 50 to 100 pg every 6 to 12 hours suppressed basal gastric acid secretion and restored the BAO/MAO ratio to normal. The rapid and complete inhibition of gastric acid secretion led to 159 a striking clinical improvement and made it possible to perform surgery without other forms of preoperative preparation. A single SO-pg injection of SMS 201-995 was sufficient to control acid secretion for the duration of operation.26
Thirty-six months of therapy with SMS was able to reduce basal and pentagastrin-stimulated acid secretion with a return of responsiveness to pentagastrin and a normal BAO/MAO ratio. This occurred simultaneously with the reduction in basal and secretin-stimulated gastrin levels. However, with time, gastrin levels rose slightly as did acid secretion. There was no evidence for tachyphylaxis or receptor induction with continued treatment. Six of eight patients had excellent biochemical and clinical responses without evidence of tumor regression, but with an apparent cessation of tumor growth.
Two of our patients were quite unresponsive to SMS. The nonresponsive individuals who had high levels of gas&in had high NH*: COOH terminal gastrin ratios. We have shown this to predict metastases and the ratio is of value in monitoring progress. 23 However, we have not determined the impact of SMS on different molecular species of gastrin. The only apparent correlate of tumor response was with the level of the initial gas&in. It could not be predicted by the presence is shown with a progressive increase in basal gastrin despite increasing doses of SMS. Early in the course of her care she manifested signs and symptoms of Cushing's, but these disappeared with SMS treatment After a 3-year period, the metastases to the liver appear to be controlled, whereas metastases to bone became extensive. or absence of metastases. However. the failure of SMS to lower gastrin did appear to parallel the lack of effect on tumor mass monitored by serial CT.
Both experimental" and clinical findings'8-20 suggest that it might be possibie to use SMS as an hormonal therapy for some malignant gastroenteropancreatic endocrine tumors. Recently, in cases of vasoactive intestinal polypeptide (VIP)oma, SMS not only controlled the diarrhea,*' but also induced shrinkage of liver metastases after 5, 6, and 14 months of treatment.73'9320922 In contrast to the tumor response in VIPoma patients, gastrinomas appear to be more resistant to SMS although it has been reported that symptomatic improvement occurred in six of nine patients with metastases treated with the analog. 23 In our patients who had failed chemotherapy, SMS did not control tumor growth nor serum gastrin levels.
The mechanism of action of SMS may not lie in its direct effects per se. Incubation of the metastatic tumor with SMS did not inhibit release of gastrin but stimulated it: in contrast to findings reported by others. 24 In the reported study, no distinction was made between the type of tumors and suppression of Ca++-stimulated and not basal gastrin was found. The unresponsiveness of metastatic tumors in vitro may reflect loss of receptors for SMS'" from undifferentiated tumors or the failure of SMS to release inhibitors of cell growth. Patients with the MEN-l syndrome with gasVinomas have been reported as having a growth factor in their plasma that is capable of stimulating bovine parathyroid cell growth in culture.25 However, no data are available on the effects of SMS on the growth factor. Alternatively, SMS may affect turn& growth by altering local growth promoters or tumor blood flow. A reduction in tumor blood ilow induced by SMS has been reported previously in one patient.7 However, further studies are required to establish this mode of action of SMS. Tumors that elaborate large amounts of gastrin appear to be refractory and there seems to be a ~lationship between cessation of tumor growth and the biochemical response. Also, it appears that secretion of hormones other than gastrin may alter responsiveness.
The simultaneous occurrence of Cushing's and ZollingerEllison syndromes has been reported before?6.27 In our three patients in whom the syndromes coexisted, ACTH levels were raised in only one of the three. All three of our patients had a long-standing history of Zollinger-Ellison syndrome before the occurrence of Cushing's syndrome. In two patients, there were already widespread me&stases when Cushing's syndrome occurred and in one patient, liver metastases were detected soon after the appearance of Cushing's syndrome. The emergence of ectopic ACTH production associated with an advanced stage of malignancy is an interesting problem. A review by Clark and Carney in 1984' showed that 88% of the pancreatic islet cell tumors associated with Gushing's syndrome had metastatic disease at the time of diagnosis. On reviewing the 12 patients with occurrence of both Cushing's and Zollinger-Ellison syndromes reported in the literature, 10 of them had metastases at the time when Cushing's syndrome appeared. One developed liver metastasis 6 months after the diagnosis and the last one, who had a malignant gastrinoma confirmed by histologic study, unfortunately died in the early postoperative period. A study of 30 patients with ectopic ACTH-producing tumors by Imura et al in 1975*' showed that adrenocokical hyperfunction was present in 6 1% at first examination and developed in a further 18% in the subsequent course of the disease. It was suggested that a specific cell line that elaborated ACTH might proliferate as the tumor progressed and reveal itself at an advanced stage of the disease. It was also suggested by Bustros and Baylin in 198529 that the high frequency of ACTH production in malignant tumors might imply that the gene coding for ACTH was linked to genes involved in the progression of a malignant process. It is of interest that in one of our patients the tumor was positive for ACTH, as well as MSH, suggesting the production of proopiomelan~okin by the tumor. Further understanding in the regulation of hormone gene expression in tumors by recombinant DNA techniques may provide clues to explain the observed association of ectopic cokicotropin production in the advanced stages of malignancy. From the clinical point of view, the occurrence of Cushing's syndrome in patients with gastrinoma suggests a malignant process as illustrated in the clinical course of our patients. None of our cases were responsive to SMS and it seems that cokicotropin production heralds unresponsivene~ to the analog.6
SUMMARY
We have used the gastrinoma syndrome to examine the effects of SMS. Acutely, SMS decreased acid secretion and restored the BAO/MAO to normal in eight of eight patients. BasaI and secretin-stimulated gastrin responses were suppressed but not normalized. Treatment for up to 2 years with SMS controlled symptoms, suppressed serum gastrin, and suppressed acid secretion. Treatment for 1 year or longer decreased tumor secretion of gas&in and ~minished basal acid secretion, an effect that persisted for 48 hours after withdrawal of SMS. SMS treatment arrested progression of tumor growth only in patients in whom there was a reduction in gastrin and gastric acid secretion. In patients with metastatic disease who had high levels of gastrin, SMS treatment for 5 to 24 months did not inhibit tumor growth or decrease gastrin levels. In those patients in whom a reduction in the blood flow to liver tumors was shown angiographically, there was a progressive improvement in hormone secretion and in tumor size in the ensuing year of t~atment, suggesting that a major target of SMS is the vascular supply of the tumors. Tumors shown to produce peptides other than gas&in, for example ACTH, were found to be markedly resistant to the action of SMS and continued to grow in an unbridled manner.
